Chief Financial Officer · 4D Molecular Therapeutics, Inc. (FDMT)

Kristian Humer

FY2025 is the first fiscal year CompBrief holds for Kristian Humer as a named executive officer of 4D Molecular Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$3,990,903

Compensation figures as of the proxy filed April 28, 2026 (DEF 14A).

Kristian Humer compensation by year

4D Molecular Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as 4D Molecular Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$66,000
Bonus$50,000
Stock awards$0
Option awards$3,874,656
Non-equity incentive$0
Pension and deferred compensation$0
All other$247
Total$3,990,903

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: 4D Molecular Therapeutics, Inc. DEF 14A filed April 28, 2026, accession 0001140361-26-017427, and prior-year filings. Open the filing on EDGAR.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option480,000—$10.51

Per the Outstanding Equity Awards at Fiscal Year-End table in 4D Molecular Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

4D Molecular Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Kristian Humer · this pageChief Financial Officer$3,990,903
David KirnPresident and Chief Executive Officer$2,051,343
Fariborz KamalFormer Chief Operating Officer & President$1,441,573

The full 4D Molecular Therapeutics compensation record

free company brief

This page is one person within 4D Molecular Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order 4D Molecular Therapeutics's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are 4D Molecular Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy